Cognetivity Neurosciences Releases Latest Version of AI-powered Brain Health Assessment Platform
Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that it has released an updated version of its flagship tool, CognICA™.CognICA is a unique platform for the assessment and monitoring of brain health: powered by...
2023-02-14 8:30 AM EST
Cognetivity Neurosciences' CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease-Modifying Therapy
Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that its flagship CognICA™ tool has demonstrated effectiveness in tracking cognitive function during the treatment of Alzheimer's disease patients with the...
2023-01-24 9:00 AM EST
Cognetivity Neurosciences Provides Update on 2022 Corporate Achievements
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, has provided an update on its corporate achievements during 2022, which position the company for continued, rapid growth in 2023.Key among Cognetivity's 2022 achievements was the...
2023-01-10 9:00 AM EST
Cognetivity Neurosciences' Brain Health Platform Cited as Case Study as Part of Early Dementia Detection Policy Recommendations by Alzheimer's Research UK
Vancouver, British Columbia--(Newsfile Corp. - December 13, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that the company and its flagship tool, CognICA™, have been cited in a newly published policy paper by the UK's leading dementia research charity, Alzheimer's Research...
2022-12-13 9:00 AM EST
Cognetivity Neurosciences to Attend HLTH 2022 in Las Vegas and Appoints New Advisory Board Member
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, today announces that it will be attending the HLTH 2022 conference next week. It also announces that it has appointed Dr. Lance Black, MD, MBID, to its advisory board with immediate...
2022-11-10 9:00 AM EST
Cognetivity Neurosciences Selected to Present to Roche Alzheimer's Team
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that it has been selected by the multinational health company Roche to present at Roche Digital Innovation Week 2022.Roche Digital Innovation Week is a global one-week...
2022-11-07 9:00 AM EST
Cognetivity Neurosciences Announces Successful Completion of Funding Round
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity") is pleased to announce the successful completion of its non-brokered private placement; the offering being oversubscribed with a final amount of $4,502,478 being raised, resulting in the issuance of 15,525,786 convertible preferred shares (the "Preferred Shares") of the Company at a price of $0.29 per Preferred Share (the...
2022-10-27 9:00 AM EDT
Cognetivity Neurosciences Announces Private Placement of Convertible Preferred Shares
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity") is pleased to announce, that it intends to complete a non-brokered private placement of up to 10,344,828 convertible preferred shares (the “Preferred Shares”) of the Company at a price of $0.29 per Preferred Share for aggregate proceeds of up to $3,000,000 (the “Private Placement”). Each Preferred Share is convertible into one...
2022-10-07 6:00 PM EDT
Cognetivity Neurosciences Announces Commercial Pilot with Large US Healthcare Provider
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, today announces that it has signed an agreement to conduct a broad-scale paid pilot project (the "Paid Project") with a large national US provider of healthcare services (the "Client").The...
2022-09-20 9:15 AM EDT
Cognetivity Neurosciences Collaborating With Baylor College of Medicine in Ground-Breaking Study on OCD
Vancouver, British Columbia--(Newsfile Corp. - September 13, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that its Integrated Cognitive Assessment ("ICA") technology in the form of the FDA-registered CognICATM, will be deployed in a multicenter clinical study (the...
2022-09-13 6:00 AM EDT